Actively Recruiting
Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma
Led by Anhui Provincial Hospital · Updated on 2023-12-26
70
Participants Needed
1
Research Sites
178 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Chemoradiotherapy has been a standard modality for inoperable locally advance esophageal carcinoma. The goal of this randomized control study is to compare the feasibility, and survival benefits of whole-course immunonutrition combined with chemoradiotherapy±ICIs for local advanced patients with inoperable esophageal squamous cell carcinoma. The main questions it aims to answer are: • If the feasibility and safety of whole-course immunonutrition combined with chemoradiotherapy±ICIs is better. • If the survival benefits (1, 2 and 3-years progression free survival) of whole-course immunonutrition combined with chemoradiotherapy±ICIs is longer. The Experimental group will receive a combination immunonutrition of omega-3 fatty acids, and glutamine, whereas the control group will receive standard formula.
CONDITIONS
Official Title
Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 85 years old
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- Diagnosis of esophageal squamous cell carcinoma
- Tumor stage cT2-4aN0-3M0 confirmed by radiological examination according to AJCC 8th edition
- Cancer considered unresectable at initial diagnosis by thoracic surgeons
- No prior treatment for esophageal cancer
- No contraindications for adjuvant chemoradiotherapy
- Signed informed consent provided
You will not qualify if you...
- Age younger than 18 years or older than 85 years
- Eastern Cooperative Oncology Group (ECOG) performance status greater than 2
- Esophageal adenocarcinoma, small-cell cancer, or other pathological types besides squamous cell carcinoma
- Tumor stages cT1anyNM0, cT4banyNM0, or any cTanyNM0 not meeting inclusion criteria
- Cancer considered resectable at initial diagnosis by thoracic surgeons
- Previous chemotherapy, radiotherapy, or other cancer treatments
- Contraindications for chemoradiotherapy
- No signed informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Anhui provincial hospital
Hefei, China
Actively Recruiting
Research Team
D
dong qian, M.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here